Valuation
- Market cap
- 1,166,630,000
- Revenue TTM
- $0
- Net income TTM
- $-137,950,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 763,000
- Avg volume
- 638,014
- Day's range
- $17.56 – $18.96
- Shares out
- 66,173,000
- Stochastic %K
- 1%
- Beta
- -0.70
- Analysts
- Strong Sell
- Price target
- $34.62
Company profile
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018...
Show more
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 468 4219
- Website
- https://www.bicara.com
- Address
- 116 Huntington Avenue, Suite 703, Boston, United States
Latest news
No headlines yet.
